Aktis Oncology, Inc. Common stock vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| AKTS | JNJ | |
|---|---|---|
| Market Cap | $1.33 billion | $628.65 billion |
| Revenue (TTM) | — | $97.93 billion |
| Net Income (TTM) | — | $21.04 billion |
JNJ leads on 1 of 1 size & scale factors.
Valuation
| AKTS | JNJ | |
|---|---|---|
| P/E Ratio | — | 30.20 |
| Price / Book | 2.62 | 7.40 |
| Price / Sales | — | 6.42 |
AKTS leads on 1 of 1 valuation factors.
Profitability
| AKTS | JNJ | |
|---|---|---|
| Net Margin | — | 21.48% |
| Return on Equity | — | 24.76% |
AKTS and JNJ split the profitability factors evenly.
Dividend
| AKTS | JNJ | |
|---|---|---|
| Dividend Yield | — | 2.06% |
| Payout Ratio | — | 62.18 |
AKTS and JNJ split the dividend factors evenly.
Risk & Sentiment
| AKTS | JNJ | |
|---|---|---|
| Short Interest | 1.68% | 0.67% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: AKTS overview, AKTS financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.